Higher-than-expected rate of gene mutations seen in Parkinson's patients
By Nancy Lapid
July 30 (Reuters) -A higher-than-expected prevalence of gene mutations in Parkinson’s disease patients suggests genetic testing should be offered to them more broadly, researchers said on Monday in the medical journal Brain.
Genetic profiling performed in more than 8,000 patients of varying races and ethnicities, all with Parkinson's disease, showed 13% had a genetic form of the progressive brain disorder, the researchers found.
That rate was 18% in patients with known risk factors, such as an earlier age at onset, Parkinson’s disease in a first-degree relative, or certain ancestry such as Ashkenazi Jewish, Spanish Basque or North African Berber.
Among patients with no known risk factors, more than 9% had a predisposing genetic mutation.
With new gene-specific drugs for the disease entering the research pipeline, the implications of the findings are significant, the researchers said.
Previous studies had suggested that about 5% to 10% of Parkinson’s disease cases were linked with genetic variants – and most of those studies had been limited to patients with known risk factors.
Presently, only a small fraction of people with Parkinson’s disease receive genetic testing, largely because neurologists are uncomfortable with their knowledge of Parkinson’s disease genetics, access to genetic counselors is limited, and the identification of a genetic basis has been unlikely to impact a patient’s treatment, said James Beck, senior vice president and chief scientific officer of the Parkinson’s Foundation, the study’s sponsor.
But with recent advances, doctors “are now on the cusp of figuring out how to treat patients based on genetics,” Beck said.
With trials of gene-specific treatments underway, and genetic results potentially impacting disease prognosis and shedding light on familial risks, clinical genetic testing should be offered to everyone with Parkinson’s disease, the research team concluded.
In the meantime, Beck said, anyone with Parkinson’s disease can enroll in the PDGENE study and receive free genetic testing, here: https://www.parkinson.org/advancing-research/our-research/pdgeneration.
Reporting by Nancy Lapid; editing by Stephen Coates
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
